Cingulate Inc. (CINGW) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Kansas City, KS, United States. The current CEO is Shane J. Schaffer.
CINGW has IPO date of 2021-12-08, 13 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $141.82K.
Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.
